Showing results (2621-2630 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 5, 2019
Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopeciaJincheng Yang, Kun Chen, Bin Wang, et al.
Investigational New Drugs|July 3, 2019
Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasisMasashi Ishikawa, Satoru Iwasa, Kengo Nagashima, et al.
Investigational New Drugs|October 10, 2018
Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature reviewHyeon Cheun, Miso Kim, Hajeong Lee, et al.
Investigational New Drugs|October 10, 2018
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancerAmit Mahipal, Sri Harsha Tella, Anuhya Kommalapati, et al.
Investigational New Drugs|January 1, 1987
Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithineC A Griffin, M Slavik, S C Chien, et al.
Investigational New Drugs|January 1, 1987
Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumorsC L Vogel, E Gorowski, E Davila, et al.
Investigational New Drugs|February 4, 2010
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimensJaafar Bennouna, Istvan Lang, Manuel Valladares-Ayerbes, et al.
Investigational New Drugs|September 20, 2018
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumorsAntonio Jimeno, Kathleen N Moore, Michael Gordon, et al.
Investigational New Drugs|June 27, 2019
A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated ParonychiaKara D Capriotti, Milan Anadkat, Jennifer Choi, et al.
Investigational New Drugs|June 27, 2019
Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cellsMaria Chiara Proto, Donatella Fiore, Giovanni Forte, et al.
Pageof 372